BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Mult Scler Relat Disord 2020;43:102174. [PMID: 32464584 DOI: 10.1016/j.msard.2020.102174] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Bhise V, Dhib-Jalbut S. Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological Perspectives. Neurotherapeutics 2021;18:244-51. [PMID: 33533012 DOI: 10.1007/s13311-021-01008-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Cohan SL, Hendin BA, Reder AT, Smoot K, Avila R, Mendoza JP, Weinstock-Guttman B. Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). CNS Drugs 2021;35:743-67. [PMID: 34228301 DOI: 10.1007/s40263-021-00822-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Alnajashi H, Jabbad R. Behavioral practices of patients with multiple sclerosis during Covid-19 pandemic. PLoS One 2020;15:e0241103. [PMID: 33091088 DOI: 10.1371/journal.pone.0241103] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
4 Landi D, Ponzano M, Nicoletti CG, Cecchi G, Cola G, Mataluni G, Mercuri NB, Sormani MP, Marfia GA. Adherence to social distancing and use of personal protective equipment and the risk of SARS-CoV-2 infection in a cohort of patients with multiple sclerosis. Mult Scler Relat Disord 2020;45:102359. [PMID: 32663793 DOI: 10.1016/j.msard.2020.102359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 [DOI: 10.1101/2021.02.08.21251316] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Giovannoni G. How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies? Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103803] [Reference Citation Analysis]
7 Hughes R, Whitley L, Fitovski K, Schneble HM, Muros E, Sauter A, Craveiro L, Dillon P, Bonati U, Jessop N, Pedotti R, Koendgen H. COVID-19 in ocrelizumab-treated people with multiple sclerosis. Mult Scler Relat Disord 2021;49:102725. [PMID: 33482590 DOI: 10.1016/j.msard.2020.102725] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
8 Mallucci G, Zito A, Baldanti F, Gastaldi M, Fabbro BD, Franciotta D, Bergamaschi R. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients. Mult Scler Relat Disord 2021;49:102754. [PMID: 33609958 DOI: 10.1016/j.msard.2021.102754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Habek M, Jakob Brecl G, Bašić Kes V, Rogić D, Barun B, Gabelić T, Emeršič A, Horvat Ledinek A, Grbić N, Lapić I, Šegulja D, Đurić K, Adamec I, Krbot Skorić M. Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study. J Neuroimmunol 2021;359:577696. [PMID: 34418815 DOI: 10.1016/j.jneuroim.2021.577696] [Reference Citation Analysis]
10 Winchester N, Calabrese C, Calabrese LH. The Intersection of COVID-19 and Autoimmunity: What is Our Current Understanding? Pathog Immun 2021;6:31-54. [PMID: 33969248 DOI: 10.20411/pai.v6i1.417] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Diaz de la Fe A, Peláez Suárez AA, Fuentes Campos M, Cabrera Hernández MN, Goncalves CA, Schultz S, Siniscalco D, Robinson-Agramonte MA. SARS-CoV-2 Infection and Risk Management in Multiple Sclerosis. Diseases 2021;9:32. [PMID: 33921878 DOI: 10.3390/diseases9020032] [Reference Citation Analysis]
12 Piñar Morales R, Ramírez Rivas MA, Barrero Hernández FJ. SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis. Neurologia (Engl Ed) 2021:S2173-5808(21)00079-1. [PMID: 34103271 DOI: 10.1016/j.nrleng.2021.03.002] [Reference Citation Analysis]
13 Mahboubi Mehrabani M, Karvandi MS, Maafi P, Doroudian M. Neurological complications associated with Covid-19; molecular mechanisms and therapeutic approaches. Rev Med Virol 2022;:e2334. [PMID: 35138001 DOI: 10.1002/rmv.2334] [Reference Citation Analysis]
14 Zabalza A, Cárdenas-Robledo S, Tagliani P, Arrambide G, Otero-Romero S, Carbonell-Mirabent P, Rodriguez-Barranco M, Rodríguez-Acevedo B, Restrepo Vera JL, Resina-Salles M, Midaglia L, Vidal-Jordana A, Río J, Galan I, Castillo J, Cobo-Calvo Á, Comabella M, Nos C, Sastre-Garriga J, Tintore M, Montalban X. COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. Eur J Neurol 2021;28:3384-95. [PMID: 33340215 DOI: 10.1111/ene.14690] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 19.0] [Reference Citation Analysis]
15 Thanou A, Sawalha AH. SARS-CoV-2 and Systemic Lupus Erythematosus. Curr Rheumatol Rep 2021;23:8. [PMID: 33511495 DOI: 10.1007/s11926-020-00973-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
16 Capone F, Motolese F, Luce T, Rossi M, Magliozzi A, Di Lazzaro V. COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review. Mult Scler Relat Disord 2021;48:102734. [PMID: 33429305 DOI: 10.1016/j.msard.2020.102734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
17 Drulovic J, Ivanovic J, Martinovic V, Tamas O, Veselinovic N, Cujic D, Gnjatovic M, Mesaros S, Pekmezovic T. HUMORAL RESPONSE TO SARS-CoV-2 AND COVID-19 VACCINES IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH IMMUNE RECONSTITUTION THERAPIES. Mult Scler Relat Disord 2021;54:103150. [PMID: 34298478 DOI: 10.1016/j.msard.2021.103150] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, Schmierer K, Giovannoni G, Amor S. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 2020;202:149-61. [PMID: 32671831 DOI: 10.1111/cei.13495] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 37.5] [Reference Citation Analysis]
19 Viswanathan S. Management of Idiopathic CNS inflammatory diseases during the COVID-19 pandemic: Perspectives and strategies for continuity of care from a South East Asian Center with limited resources. Mult Scler Relat Disord 2020;44:102353. [PMID: 32653804 DOI: 10.1016/j.msard.2020.102353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Etemadifar M, Aghababaee A, Sedaghat N, Rayani M, Nouri H, Abhari A, Salari M, Majdinasab N, Ghiasian M, Bayati A, Nabavi SM, Mansouri A. WITHDRAWN: Incidence and mortality of COVID-19 in Iranian multiple sclerosis patients treated with disease-modifying therapies. Rev Neurol (Paris) 2020:S0035-3787(20)30660-3. [PMID: 33039152 DOI: 10.1016/j.neurol.2020.08.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Sellner J, Rommer PS. Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. Vaccines (Basel) 2021;9:99. [PMID: 33525459 DOI: 10.3390/vaccines9020099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
22 Matías-Guiu J, Montero-Escribano P, Pytel V, Porta-Etessam J, Matias-Guiu JA. Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab. Mult Scler Relat Disord 2020;44:102297. [PMID: 32554284 DOI: 10.1016/j.msard.2020.102297] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
23 Sen S, Karabudak R, Schiavetti I, Demir S, Ozakbas S, Tutuncu M, Petek Balci B, Turan OF, Uzunkopru C, Koseoglu M, Yetkin MF, Gunduz T, Gumus H, Kale Icen N, Carmisciano L, Terzi M, Acar P, Gungor Dogan I, Baba C, Tuncer A, Uygunoglu U, Sormani MP, Efendi H, Siva A; Turkish MS Study Group. The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals? Mult Scler Relat Disord 2021;52:102968. [PMID: 33940495 DOI: 10.1016/j.msard.2021.102968] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 Celius EG. Normal antibody response after COVID-19 during treatment with cladribine. Mult Scler Relat Disord 2020;46:102476. [PMID: 32882501 DOI: 10.1016/j.msard.2020.102476] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
25 von Oertzen TJ, Macerollo A, Leone MA, Beghi E, Crean M, Oztuk S, Bassetti C, Twardzik A, Bereczki D, Di Liberto G, Helbok R, Oreja-Guevara C, Pisani A, Sauerbier A, Sellner J, Soffietti R, Zedde M, Bianchi E, Bodini B, Cavallieri F, Campiglio L, Maia LF, Priori A, Rakusa M, Taba P, Moro E, Jenkins TM; EANcore COVID-19 task force. EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic. Eur J Neurol 2021;28:7-14. [PMID: 33058321 DOI: 10.1111/ene.14521] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
26 Kulikowska J, Kulczyńska-Przybik A, Mroczko B, Kułakowska A. The Significance of COVID-19 Immunological Status in Severe Neurological Complications and Multiple Sclerosis-A Literature Review. Int J Mol Sci 2021;22:5894. [PMID: 34072715 DOI: 10.3390/ijms22115894] [Reference Citation Analysis]
27 Cobo-Calvo A, Zabalza A, Río J, Arrambide G, Otero-Romero S, Tagliani P, Cárdenas-Robledo S, Castillo M, Espejo C, Rodriguez M, Carbonell P, Rodríguez B, Midaglia L, Vidal-Jordana Á, Tur C, Galan I, Castillo J, Comabella M, Nos C, Auger C, Tintoré M, Rovira À, Montalban X, Sastre-Garriga J. Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. J Neurol 2022. [PMID: 35001198 DOI: 10.1007/s00415-021-10958-z] [Reference Citation Analysis]
28 Etemadifar M, Nouri H, Maracy MR, Akhavan Sigari A, Salari M, Blanco Y, Sepúlveda M, Zabalza A, Mahdavi S, Baratian M, Sedaghat N. Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis. Rev Neurol (Paris) 2021:S0035-3787(21)00743-8. [PMID: 34836608 DOI: 10.1016/j.neurol.2021.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Prosperini L, Tortorella C, Haggiag S, Ruggieri S, Galgani S, Gasperini C. Determinants of COVID-19-related lethality in multiple sclerosis: a meta-regression of observational studies. J Neurol 2022. [PMID: 34984514 DOI: 10.1007/s00415-021-10951-6] [Reference Citation Analysis]
30 Moura J, Nascimento H, Ferreira I, Samões R, Teixeira C, Lopes D, Boleixa D, Sousa AP, Santos E, Silva AM. SARS-CoV-2 infection in patients with neuroimmunological disorders in a tertiary referral centre from the north of Portugal. Multiple Sclerosis and Related Disorders 2022;63:103893. [DOI: 10.1016/j.msard.2022.103893] [Reference Citation Analysis]
31 Dewanjee S, Vallamkondu J, Kalra RS, Puvvada N, Kandimalla R, Reddy PH. Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic. Mol Neurobiol 2021. [PMID: 34169443 DOI: 10.1007/s12035-021-02450-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Baker D, Asardag AN, Quinn OA, Efimov A, Kang AS. Anti-drug antibodies to antibody-based therapeutics in multiple sclerosis. Hum Antibodies 2021. [PMID: 34397407 DOI: 10.3233/HAB-210453] [Reference Citation Analysis]
33 Gomez-Mayordomo V, Montero-Escribano P, Matías-Guiu JA, González-García N, Porta-Etessam J, Matías-Guiu J. Clinical exacerbation of SARS-CoV2 infection after fingolimod withdrawal. J Med Virol 2021;93:546-9. [PMID: 32644205 DOI: 10.1002/jmv.26279] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
34 Baker D, Macdougall A, Kang AS, Schmierer K, Giovannoni G, Dobson R. Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals? Clinical and Experimental Immunology 2022;207:263-71. [DOI: 10.1093/cei/uxab015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
35 Sahraian MA, Azimi A, Navardi S, Ala S, Naser Moghadasi A. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord 2020;46:102472. [PMID: 32890817 DOI: 10.1016/j.msard.2020.102472] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 15.0] [Reference Citation Analysis]
36 Schmierer K, Sørensen PS, Baker D. Highly effective disease-modifying treatment as initial MS therapy. Curr Opin Neurol 2021;34:286-94. [PMID: 33840776 DOI: 10.1097/WCO.0000000000000937] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Rostami Mansoor S, Ghasemi-Kasman M. Impact of disease-modifying drugs on the severity of  COVID-19 infection in multiple sclerosis patients. J Med Virol 2021;93:1314-9. [PMID: 33044760 DOI: 10.1002/jmv.26593] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
38 Fernández-Díaz E, Gracia-Gil J, García-García JG, Palao M, Romero-Sánchez CM, Segura T. COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab. Mult Scler Relat Disord 2020;45:102402. [PMID: 32711297 DOI: 10.1016/j.msard.2020.102402] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
39 Tobin D, Vige R, Calder PC. Review: The Nutritional Management of Multiple Sclerosis With Propionate. Front Immunol 2021;12:676016. [PMID: 34394076 DOI: 10.3389/fimmu.2021.676016] [Reference Citation Analysis]
40 Reyes S, Cunningham AL, Kalincik T, Havrdová EK, Isobe N, Pakpoor J, Airas L, Bunyan RF, van der Walt A, Oh J, Mathews J, Mateen FJ, Giovannoni G. Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. J Neuroimmunol 2021;357:577627. [PMID: 34139567 DOI: 10.1016/j.jneuroim.2021.577627] [Cited by in F6Publishing: 1] [Reference Citation Analysis]